Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Teva Pharma Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (174)
ARTG (106)
Prescription medicine registration (25)
Australian public assessment report (AusPar) (7)
Prescription medicine decision summary (3)
Section 14, TGO91 consent (2)
Designation or determination (1)
Prescription medicine evaluation (1)

Date

2026 (3)
2025 (32)
2024 (120)
2023 (16)
2022 (13)
2021 (61)
2020 (23)
2019 (9)
2018 (5)
2017 (7)
2016 (18)
2015 (2)
2012 (1)
2011 (4)
2006 (3)
1995 (2)

Search

Sponsor content

319 result(s) found, displaying 241 to 250

EPIRUBE epirubicin hydrochloride 200 mg/100 mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
EPIRUBE epirubicin hydrochloride 150 mg/75 mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
EPIRUBE epirubicin hydrochloride 10 mg/5 mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
BLENAMAX bleomycin sulfate 15000IU powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
METHYLPHENIDATE SANDOZ XR, METHYLPHENIDATE XR ARX (Teva Pharma Australia Pty Ltd)

10 June 2021

Prescription medicine registration

Active ingredients: methylphenidate hydrochloride.
Austedo

9 June 2021

Prescription medicine decision summary

Australian prescription medicine decision summary
LENALIDOMIDE-TEVA, TE- LENALIDOMIDE, TE-LENALIDOMIDE (Teva Pharma Australia Pty Ltd)

4 June 2021

Prescription medicine registration

Active ingredients: lenalidomide hydrochloride monohydrate.
AUSTEDO (Teva Pharma Australia Pty Ltd)

26 May 2021

Prescription medicine registration

Active ingredients: deutetrabenazine.
COPAXONE PEN glatiramer acetate 40 mg/1 mL solution for injection prefilled pen (316728)

17 April 2019

ARTG

Australian Register of Therapeutic Goods (ARTG) information for COPAXONE PEN glatiramer acetate 40 mg/1 mL solution for injection prefilled pen.
DASATINIB-TEVA, TE-DASATINIB (Teva Pharma Australia Pty Ltd)

11 March 2021

Prescription medicine registration

Active ingredients: dasatinib.

Pages

First page
Previous page
…
Page 21
Page 22
Page 23
Page 24
Current page 25
Page 26
Page 27
Page 28
Page 29
…
Next page
Last page

Is there anything wrong with this page?

Help us improve

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.